PDCD1 and neoplasm: Two key mechanisms may underlie these events: hidden autoimmunity, where PD‐1 blockade disrupts immune tolerance, activating pre‐existing autoimmune responses; and molecular mimicry, where structural similarities between tumor antigens and neuromuscular junction proteins trigger T‐cell cross‐reactivity and neuromuscular damage [35].